A detailed history of Ubs Oconnor LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 49,961 shares of ALKS stock, worth $1.54 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
49,961
Holding current value
$1.54 Million
% of portfolio
0.1%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$23.01 - $28.55 $622,167 - $771,963
-27,039 Reduced 35.12%
49,961 $1.4 Million
Q2 2024

Aug 14, 2024

BUY
$23.21 - $27.24 $1.79 Million - $2.1 Million
77,000 New
77,000 $1.86 Million
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $205,515 - $252,211
8,794 New
8,794 $243,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.05B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.